Cargando…
Experience with etanercept, tocilizumab and interleukin-1 inhibitors in systemic onset juvenile idiopathic arthritis patients from the BIKER registry
BACKGROUND: Treatment of systemic onset juvenile idiopathic arthritis JIA (sJIA), although dramatically improved, remains a challenge. Experience from clinical practice will be presented using data from the German Biologics register (BiKeR) for evaluation of efficacy and safety of treatment with eta...
Autores principales: | Horneff, Gerd, Schulz, Anna Carina, Klotsche, Jens, Hospach, Anton, Minden, Kirsten, Foeldvari, Ivan, Trauzeddel, Ralf, Ganser, Gerd, Weller-Heinemann, Frank, Haas, Johannes Perter |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5700562/ https://www.ncbi.nlm.nih.gov/pubmed/29166924 http://dx.doi.org/10.1186/s13075-017-1462-2 |
Ejemplares similares
-
Long-term safety and effectiveness of etanercept in JIA: an 18-year experience from the BiKeR registry
por: Armaroli, Giulia, et al.
Publicado: (2020) -
Comparative risk of infections among real-world users of biologics for juvenile idiopathic arthritis: data from the German BIKER registry
por: Thiele, Franz, et al.
Publicado: (2021) -
Comparison of treatment response, remission rate and drug adherence in polyarticular juvenile idiopathic arthritis patients treated with etanercept, adalimumab or tocilizumab
por: Horneff, Gerd, et al.
Publicado: (2016) -
Biologic Therapies in Polyarticular Juvenile Idiopathic Arthritis. Comparison of Long‐Term Safety Data from the German BIKER Registry
por: Klein, Ariane, et al.
Publicado: (2019) -
Safety and efficacy of tocilizumab in children with systemic juvenile idiopathic arthritis
por: Horneff, G, et al.
Publicado: (2015)